Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJan262016	Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection Multi-Center, Randomized, Controlled Phase 1/2 Clinical Trial in Mobilized Peripheral Blood HCT to be Initiated in Mid-2016 Read All »	View HTML Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection 16.8 KB
Toggle SummaryMar132017	Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy SAN DIEGO, March 13, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Read All »	View HTML Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy 17.8 KB
Toggle SummaryMay102017	Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Read All »	View HTML Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors 17.6 KB
Toggle SummaryJul292014	Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders Phase 1b PROVIDE Study in Pediatric Patients with Inherited Metabolic Disorders Expected to Begin in 4Q14 Read All »	View HTML Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders 16.8 KB
Toggle SummaryFeb062019	Fate Therapeutics Announces FDA Clearance of IND Application for World’s First Cell Therapy Derived from an Engineered Pluripotent Stem Cell FT516 Off-the-Shelf NK Cell Cancer Immunotherapy Cleared for Clinical Investigation by FDA Product Candidate Derived from Clonal Master iPSC Line Engineered with Novel CD16 Fc Receptor Clinical Trial to Evaluate Multi-dose Cycles of FT516 for Treatment of Hematologic Malignancies, including in Read All »	View HTML
Toggle SummarySep032019	Fate Therapeutics Announces FDA Clearance of IND Application for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy FT596 Product Candidate Derived from Clonal Master iPSC Line Engineered with Three Anti-Tumor Functional Components Designed to Overcome CD19 Antigen Escape and Improve Durability of Response by Targeting Multiple Tumor-associated Antigens Off-the-Shelf Availability of FT596 Enables Rapid Read All »	View HTML
Toggle SummaryMay202020	Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Combination with Anti-CD38 Monoclonal Antibody Therapy for Multiple Myeloma Off-the-shelf NK Cell Product Candidate Derived from Clonal Master iPSC Line Engineered with Three Functional Read All »	View HTML
Toggle SummaryApr232014	Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients Phase 1b PROMPT Study in Hematologic Malignancies Expected to Begin in Mid-2014 Read All »	View HTML Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients 16.9 KB
Toggle SummaryJun282022	Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration Expanded Partnership Enables Development of both CAR NK and CAR T-cell Collaboration Candidates for Solid Tumors SAN DIEGO , June 28, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML
Toggle SummaryJan132020	Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood FT516 IND Application Cleared by FDA for Advanced Solid Tumors in Combination with PDL1-, EGFR- and HER2-targeting Therapeutic Antibodies Published Preclinical Data Demonstrate iPSC-derived NK Cells Engineered with High-affinity, Non-cleavable CD16 Enhance the Efficacy of Antibody Therapy SAN DIEGO Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.